Northwestern Kellogg alumnus, Kent Hawryluk ’07, gifted $3 million to the business school, establishing the Hawryluk Biopharmaceutical Scholars Endowed Fund. The fund builds upon the existing Program on Healthcare at Kellogg (HCAK). The scholars will be Full-Time MBA students with a demonstrated interest in healthcare. They will receive scholarships and benefit from dedicated co-curricular programming. Additionally, the scholars will engage alumni and other experts in the healthcare management field, particularly in biopharmaceuticals, through treks to industry hubs, presentations from field leaders and mentorship. Moreover, successive cohorts of scholars are expected to form a supportive career network.
“Kellogg has a unique opportunity to be the number one business school in all facets of healthcare,” Hawryluk said. “With Kellogg’s ideal location in the Chicago area, there is potential to nurture a pipeline of talent in biopharmaceuticals and support related entrepreneurship. We’re really breaking ground in this space.” Hawryluk is a serial entrepreneur in the healthcare space. Currently, he is co-founder, president and CEO of MBX Biosciences. Additionally, he was a co-founder and chief business officer of Avidity Biosciences (RNA), a publicly traded genetic medicines company. Previously, he co-founded Marcadia Biotech and MB2.
Hawryluk also collaborated with Professor Craig Garthwaite, who leads HCAK, to develop the benefits of the fund. Garthwaite commented, “Within healthcare, the biopharmaceutical sector presents meaningful challenges and opportunities. Success requires understanding both scientific advances and commercial opportunities.”
See the full announcement here.
